CNQ-T 0.22 HBM-T -0.01 SLF-T 0.34 KEY-T 0.38 BIP.UN-T 0.26 POW-T -0.14 BBD.B-T 1.16
Daily Stock Opinions and Ratings
The ultimate 360° Tracker Your financial life in one place, automatically
Stockchase Opinions

Norman Levine Genentech DNA-N HOLD Jul 21, 2008

Once a takeover bid comes in, it no longer trades on fundamentals. If you already own, keep the stock and wait to see what happens. You could take a bit of profit here.
Norman LevineNorman Levine
Unknown
Unlock Rating
$93.880

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

TOP PICK

Genentech(DNA-N)

Aug 29, 2001
Growing revenue profits annually 25%. Good products. Good value at this price.
John Sinkins, CFAJohn Sinkins, CFA
Unknown
Unlock Rating
$47.250

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Genentech(DNA-N)

May 24, 2005
Model price is $25.24. Very expensive.
Brian Acker, CABrian Acker, CA
No
Unlock Rating
$78.600

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

Genentech(DNA-N)

Jul 13, 2005
The biotech sector is one of the first growth oriented groups that turned up and has been relatively strong all year. Likes this one because it has a diversified revenue line. Growing cash flow.
David BurrowsDavid Burrows
Owned
Unlock Rating
$86.650

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Genentech(DNA-N)

Jun 07, 2007
One of the largest bio-tech firms in the world. He thinks there is not enough control, in knowing how research is going to be able to proceed. (phase 1 through phase 6). Instead he uses PBE-A which is a portfolio. Less exciting but more rewarding long term.
Charles LannonCharles Lannon
No
Unlock Rating
$74.901

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Genentech(DNA-N)

Jun 21, 2007
The model price is $48.70, a negative 35% differential. Would choose Amgen (AMGN-Q), which he owns.
Brian Acker, CABrian Acker, CA
No
Unlock Rating
$75.970

Stock price when the opinion was issued

biotechnology pharmaceutical

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Latest Buy Signals

WCP-T 0.09$8.28
PNG-X -0.08$2.37
FTG-T 0.33$9.25
WMT-N 0.13$95.22
COST-Q 1.38$978.54

Today's Top Picks

CNQ-T 0.22$40.9
HBM-T -0.01$10.29
SLF-T 0.34$81.16
KEY-T 0.38$43
BIP.UN… 0.26$40.23

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

MU-Q -1.22$78.56
HPQ-N 0.11$25.39
LSPD-T -0.13$14.08
TSLA-Q 0.93$285.88
ARE-T 0.5$15.9

Most Recent Experts

Michael Sprung

Michael Sprung

Sprung Investment Management

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Stockchase Insights

Stockchase Insights

5i Research

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Greg Newman

Greg Newman

Scotia Wealth Management

© Stockchase Inc.